CCR4 and peripheral T-cell lymphoma, not otherwise specified: A Phase II Study of the Anti-CCR4 Antibody Mogamulizumab in Patients with Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma.